Clinical trials: Thrombotic Microangiopathies
Thrombotic Thrombocytopenic Purpura, Hemolytic Uremic Syndrome
Rituximab in Patients With Relapsed or Refractory TTP-HUS
The general objective of this study is to assess the efficacy and safety of Rituximab in the management of patients with refractory or relapsed thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS).
- Trial name
- NCT00531089
- Testing
- Rituximab
- Where
- 11 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Hamilton Health Sciences Corporation
Hairy Cell Leukemia
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of…
- Trial name
- PROXY (NCT04125290)
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Thrombotic Microangiopathies
Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy
Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy
- Trial name
- NCT04784455
- Testing
- nomacopan (rVA576)
- Where
- 9 sites in United States, Poland and 1 more
- Volunteers
- 10 people
- Sponsor
- AKARI Therapeutics
Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP)
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
This is a single arm, open-label, dose escalation and expansion study to evaluate the safety, tolerability and preliminary efficacy of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA(BZE2204) in…
- Conditions
- Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP), Systemic Lupus Erythematosus(SLE)
- Trial name
- NCT07174843
- Testing
- CD19/CD22/BCMA CAR-T cells(BZE2204)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Atypical Hemolytic Uremic Syndrome
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
This is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aHUS.
- Trial name
- NCT05795140
- Testing
- Iptcaopan 200 mg
- Where
- 9 sites in Brazil, China and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Thrombotic Thrombocytopenic Purpura (TTP)
A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program
Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare blood disorder that some people are born with. It is caused by inherited changes in the ADAMTS13 gene that reduce the body's ability to produce the ADAMTS13 enzyme.
- Trial name
- NCT07429942
- Testing
- No Intervention
- Where
- 8 sites in Germany, Poland
- Volunteers
- 94 people
- Sponsor
- Takeda
Immune Thrombocytopenia, System; Lupus Erythematosus
The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of Primary ITP and SLE-Related Thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune- mediated acquired bleeding disorder, defined as a platelet count less than 100×109/L without other causes of isolated thrombocytopenia.
- Trial name
- NCT07298733
- Testing
- measuring gene expression
- Volunteers
- 300 people
- Sponsor
- Sohag University
ITP - Immune Thrombocytopenia
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
- Trial name
- NCT07093606
- Testing
- Eltrombopag
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Immune Thrombocytopenia
ITP Registry and Accompanying Biospecimen Collection
The objective of this ITP registry is to collect clinical information, including biosampling, from consenting patients with a variety of ITPs at different points in the course of their disease.
- Trial name
- ITP-Registry (NCT05152238)
- Where
- 64 sites in Germany
- Volunteers
- 1,100 people
- Sponsor
- Jena University Hospital
Immune Thrombocytopenia
Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of cyclosporin plus standard steroid compared to standard steroid monotherapy for the first-line treatment of adults with primary immune…
- Trial name
- NCT05459649
- Testing
- Cyclosporine Oral Product, Prednisone
- Where
- China
- Volunteers
- 253 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenic Purpura
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment.
- Trial name
- NYMC207 (NCT04323748)
- Testing
- rituxan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Immune Thrombocytopenia
The Combination of Prednisone and Recombinant Human Thrombopoietin for Treatment of Immune Thrombocytopenia in Pregnancy
Randomized, open-label study to compare the efficacy and safety of prednisone plus recombinant human thrombopoietin (rhTPO) compared to prednisone monotherapy for the treatment of immune thrombocytopenia in pregnancy
- Trial name
- NCT05333744
- Testing
- Prednisone, Recombinant Human TPO
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia
An Investigation of rhTPO With Different Frequencies in the Management of ITP
The project was undertaking by Qilu Hospital of Shandong University and other well-known hospitals in China. In order to study the efficacy and safety of different dose and frequency Recombinant Human thrombopoietin in treating…
- Trial name
- NCT02139501
- Testing
- Recombinant Human Thrombopoietin (rhTPO)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shandong University
Immune Thrombocytopenia
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
This was a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in…
- Trial name
- LUNA 3 (NCT04562766)
- Testing
- Rilzabrutinib
- Where
- 155 sites in United States, Argentina and 24 more
- Volunteers
- 232 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Primary Immune Thrombocytopenia
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to assess the long-term safety, tolerability and clinical efficacy of treatment with rozanolixizumab.
- Trial name
- myOpportunITy3 (NCT04596995)
- Testing
- Rozanolixizumab
- Where
- 27 sites in United States, China and 12 more
- Volunteers
- 43 people
- Sponsor
- UCB Biopharma SRL
Idiopathic Thrombocytopenic Purpura
A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501
This is a study in healthy subjects. There are two parts to the study. In the first part of the study each subject will receive a single 10mg dose of each of the four formulations of E550.
- Trial name
- NCT01549054
- Testing
- 10-mg dose of E5501 2G tablet, 10-mg dose of E5501 cyclodextrin oral solution, 10-mg dose of E5501-P21% powder
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Purpura, Thrombotic Thrombocytopenic
Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura
Congenital thrombotic thrombocytopenic purpura (TTP), also called Upshaw-Schulman Syndrome or hereditary or familial TTP is a rare, but severe disease.
- Trial name
- NCT01754545
- Sponsor
- St. Olavs Hospital
Immune Thrombocytopenia, Pregnancy
A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy
The project was undertaking by Qilu Hospital of Shandong University and other well-known hospitals in China. Aims at evaluating efficacy and safety of rhTPO in management of ITP in pregnancy.
- Trial name
- NCT02391272
- Testing
- rhTPO
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Shandong University
Immune Thrombocytopenic Purpura, Coronary Artery Disease
Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization
This study employs a dual-cohort design to develop and validate a prognostic model for Major Adverse Cardiovascular Events (MACE) following revascularization in immune thrombocytopenia (ITP) patients with Coronary Artery Disease…
- Trial name
- ITP with CAD (NCT07426107)
- Volunteers
- 600 people
- Sponsor
- Xiao Hui Zhang
Immune Thrombocytopenia, Treatment
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or had…
- Trial name
- NCT07297563
- Testing
- Rituximab, Daratumumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China